MX376183B - Composiciones para el tratamiento de rosacea. - Google Patents

Composiciones para el tratamiento de rosacea.

Info

Publication number
MX376183B
MX376183B MX2015005515A MX2015005515A MX376183B MX 376183 B MX376183 B MX 376183B MX 2015005515 A MX2015005515 A MX 2015005515A MX 2015005515 A MX2015005515 A MX 2015005515A MX 376183 B MX376183 B MX 376183B
Authority
MX
Mexico
Prior art keywords
rosacea
compositions
treatment
afflictions
symptoms
Prior art date
Application number
MX2015005515A
Other languages
English (en)
Other versions
MX2015005515A (es
Inventor
Haim Bar-Simantov
Hanan Sertchook
Ofer Toledano
Original Assignee
Sol Gel Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sol Gel Tech Ltd filed Critical Sol Gel Tech Ltd
Publication of MX2015005515A publication Critical patent/MX2015005515A/es
Publication of MX376183B publication Critical patent/MX376183B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a composiciones farmacéuticas para uso tópico (incluyendo también composiciones dermatológicas), para tratar condiciones y aflicciones de la piel, tal como rosácea y síntomas y condiciones asociadas de la misma.
MX2015005515A 2012-11-27 2012-11-27 Composiciones para el tratamiento de rosacea. MX376183B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2012/050479 WO2014083557A1 (en) 2012-11-27 2012-11-27 Compositions for the treatment of rosacea

Publications (2)

Publication Number Publication Date
MX2015005515A MX2015005515A (es) 2015-07-17
MX376183B true MX376183B (es) 2025-03-07

Family

ID=47428789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005515A MX376183B (es) 2012-11-27 2012-11-27 Composiciones para el tratamiento de rosacea.

Country Status (7)

Country Link
EP (1) EP2925296B1 (es)
JP (1) JP6423355B2 (es)
CN (2) CN104853746B (es)
CA (2) CA3051403C (es)
ES (1) ES2861431T3 (es)
MX (1) MX376183B (es)
WO (1) WO2014083557A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068673A1 (ja) * 2015-10-21 2017-04-27 マルホ株式会社 皮膚用の医薬組成物
CN109071750B (zh) 2016-03-08 2022-08-02 生活实验公司 持久化妆品组合物
US12357602B2 (en) * 2017-07-12 2025-07-15 Mayne Pharma Llc Compositions comprising encapsulated tretinoin
CN111133023B (zh) 2017-09-13 2022-10-18 生活实验公司 持久化妆品组合物
CA3074845A1 (en) 2017-09-13 2019-03-21 Living Proof, Inc. Color protectant compositions
CN111356501A (zh) 2017-11-20 2020-06-30 生活实验公司 实现持久化妆品性能的属性
AU2019257739B2 (en) 2018-04-27 2025-01-09 Living Proof, Inc. Long lasting cosmetic compositions
EP3586849A1 (en) 2018-06-29 2020-01-01 Aprofol AG Folate preparations
JP6811213B2 (ja) * 2018-07-03 2021-01-13 ソル − ゲル テクノロジーズ リミテッド 酒さの治療のための組成物
US10933046B2 (en) * 2019-02-19 2021-03-02 Sol-Gel Technologies, Ltd. Method for treatment of rosacea in patients aged 65 years and older

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406008C (en) * 2000-04-21 2011-03-15 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
GB0301577D0 (en) * 2003-01-23 2003-02-26 Edko Pazarlama Tanitim Ltd Sti Topical pharmaceutical and/or cosmetic dispense systems
FR2886850B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
WO2008057411A1 (en) * 2006-11-02 2008-05-15 Stiefel Laboratories, Inc. Kits containing benzoyl peroxide pads and another acne-treating composition, and formulations and methods of use therefor
FR2909000B1 (fr) * 2006-11-28 2009-02-06 Galderma Res & Dev S N C Snc Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations.
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
ES2912051T3 (es) * 2007-02-01 2022-05-24 Sol Gel Tech Ltd Composiciones para aplicación tópica que comprenden un peróxido y retinoide
WO2008093347A2 (en) * 2007-02-01 2008-08-07 Sol-Gel Technologies Ltd. Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
WO2009077693A2 (fr) * 2007-11-30 2009-06-25 Galderma Research & Development Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations
PT2299810T (pt) * 2008-06-05 2020-03-04 Bausch Health Ireland Ltd Formulações tópicas farmacológicas que contêm uma baixa concentração de peróxido de benzoilo em suspensão em água e um solvente orgânico miscível em água
CN102112219A (zh) * 2008-07-31 2011-06-29 溶胶凝胶技术公司 包含有效成分和金属氧化物壳的微胶囊,其制备方法及其用途
JP2012514593A (ja) * 2009-01-05 2012-06-28 ゾル−ゲル テクノロジー リミテッド 被覆した活性剤を含む局所組成物
EP2490528A4 (en) * 2009-10-21 2013-06-12 Dow Pharmaceutical Sciences METHOD FOR ANCHORING A POWDER CONTAINING BENZOYL PEROXIDE
KR20130008002A (ko) * 2009-12-31 2013-01-21 솔-겔 테크놀로지스 리미티드 코어 안정화 마이크로캡슐, 이의 제조방법 및 이의 용도
US20120064135A1 (en) * 2010-09-15 2012-03-15 Norac Pharma Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof

Also Published As

Publication number Publication date
EP2925296A1 (en) 2015-10-07
WO2014083557A1 (en) 2014-06-05
CA3051403A1 (en) 2014-06-05
CA2889199C (en) 2020-05-19
CA3051403C (en) 2021-07-20
EP2925296B1 (en) 2021-01-06
JP6423355B2 (ja) 2018-11-14
CN104853746A (zh) 2015-08-19
CA2889199A1 (en) 2014-06-05
CN108159425A (zh) 2018-06-15
MX2015005515A (es) 2015-07-17
CN104853746B (zh) 2018-02-23
ES2861431T3 (es) 2021-10-06
JP2016501205A (ja) 2016-01-18

Similar Documents

Publication Publication Date Title
MX376183B (es) Composiciones para el tratamiento de rosacea.
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12014501702A1 (en) Imidazopyrrolidinone compounds
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
GB201118656D0 (en) New compounds
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
CR20120202A (es) Métodos y composiciones para tratar cáncer
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
PH12013501600A1 (en) Novel heterocyclic derivatives
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
EA201591925A1 (ru) Терапевтические композиции и их применение
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
GT201400146A (es) Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides
IN2013MU03118A (es)
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку

Legal Events

Date Code Title Description
FG Grant or registration